Follow the attached instructions

A comprehensive overview of Gilead's strategic priorities, highlighting synergies in I&I, oncology, and virology. The portfolio includes current assets, pipeline programs, and platforms. Flagship assets and their unique mechanisms target key indications with differentiation. Competitive analysis identifies strengths and strategic gaps, while the forward view emphasizes innovation through partnerships, acquisitions, and future milestones.